Anzeige
Mehr »
Login
Freitag, 24.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1J4U0 | ISIN: US6092071058 | Ticker-Symbol: KTF
Tradegate
24.01.25
20:53 Uhr
54,67 Euro
-0,01
-0,02 %
1-Jahres-Chart
MONDELEZ INTERNATIONAL INC Chart 1 Jahr
5-Tage-Chart
MONDELEZ INTERNATIONAL INC 5-Tage-Chart
RealtimeGeldBriefZeit
54,6354,7620:55
54,6454,7620:55
GlobeNewswire (Europe)
94 Leser
Artikel bewerten:
(0)

Mondelez International, Inc.: Mondelez International Approves New $9 billion Share Repurchase Authorization and Declares Regular Quarterly Dividend

Finanznachrichten News
  • New $9 billion authorization for share repurchase
  • Company declares regular quarterly dividend of $0.47 per share
  • Confirming capital allocation priorities, including brand and capability
    reinvestment, bolt-on acquisitions, share repurchase and dividends

CHICAGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Mondelez International, Inc. (NASDAQ: MDLZ) approved a new share repurchase authorization of up to $9 billion of Class A common stock, effective January 1, 2025. The new authorization, effective until December 31, 2027, will replace the current $6 billion authorization, of which approximately $2.8 billion is presently remaining and would otherwise expire on December 31, 2025. The company may repurchase the shares in open market transactions, privately negotiated transactions or a combination of the foregoing. Share repurchases are subject to the company's discretion based on market conditions, business considerations and other factors.

The Board of Directors also declared a regular quarterly dividend of $0.47 per share of Class A common stock. This dividend is payable on January 14, 2025, to shareholders of record as of the close of business on December 31, 2024.

The company also remains committed to its key capital allocation priorities, which include reinvesting in brands and capabilities, returning capital to shareholders through share repurchases and dividends, and M&A. Given current market conditions, share repurchase remains an opportunity and key priority. The company remains committed to an acquisition strategy that is focused on bolt-on assets similar to recent acquisitions of Chipita, Clif and Ricolino.

"Our new $9 billion share repurchase authorization reflects the strength of our business with robust profit dollar and cash flow growth to reinvest in brands and capabilities while also returning significant capital to our shareholders," said Chairman and CEO Dirk Van de Put. "We continue to make significant progress against our strategy of accelerating growth and focusing our portfolio in the attractive, resilient categories of chocolate, biscuits and baked snacks. Our teams remain focused on executing against our growth agenda in a challenging and dynamic operating environment."

About Mondelez International
Mondelez International, Inc. (Nasdaq: MDLZ) empowers people to snack right in over 150 countries around the world. With 2023 net revenues of approximately $36 billion, MDLZ is leading the future of snacking with iconic global and local brands such as Oreo, Ritz, LU, Clif Bar and Tate's Bake Shop biscuits and baked snacks, as well as Cadbury Dairy Milk, Milka and Toblerone chocolate. Mondelez International is a proud member of the Standard and Poor's 500, Nasdaq 100 and Dow Jones Sustainability Index. Visit www.mondelezinternational.com or follow the company on X at x.com/MDLZ.

Forward-Looking Statements
Forward-Looking Statements This press release contains forward-looking statements. Words, and variations of words, such as "will," "may," "expect," "plan," "continue" and similar expressions are intended to identify these forward-looking statements, including, but not limited to, statements of belief or expectation and statements about Mondelez International's leadership position in snacking. These forward-looking statements are subject to change and to inherent risks and uncertainties, many of which are beyond Mondelez International's control, which could cause Mondelez International's actual results or outcomes to differ materially from those projected or assumed in these forward-looking statements. Please also see Mondelez International's risk factors, as they may be amended from time to time, set forth in its filings with the U.S. Securities and Exchange Commission, including its most recently filed Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. There may be other factors not presently known to Mondelez International or which it currently considers to be immaterial that could cause Mondelez International's actual results to differ materially from those projected in any forward-looking statements it makes. Mondelez International disclaims and does not undertake any obligation to update or revise any forward-looking statement in this press release, except as required by applicable law or regulation.

Contact:Tracey Noe (Media)Shep Dunlap (Investors)
+1 847 943 4772+1 847 943 5454
news@mdlz.comir@mdlz.com

© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.